Itm Solucin Gmbh
Clinical trials sponsored by Itm Solucin Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Radioactive drug aims to shrink Hard-to-Treat gut tumors Results expected Jun 2027 (estimated)
-
Radioactive therapy vs. pill: which works better for gut and pancreas tumors?
Disease control OngoingThis phase 3 trial tests whether a radioactive drug called 177Lu-Edotreotide (PRRT) works better than the daily pill everolimus for people with advanced neuroendocrine tumors of the gut or pancreas that can't be removed by surgery. About 324 participants are randomly assigned to …
Phase 3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Radioactive drug aims to shrink Hard-to-Treat gut tumors
Disease control OngoingThis Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see…
Phase 3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 26, 2026 16:35 UTC